Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

ChemoCentryx's Return On Capital Employed Insights

ChemoCentryx (NASDAQ:CCXI) brought in sales totaling $2.31 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 81.68%, resulting in a loss of $40.53 million. ChemoCentryx collected $17.74 million in revenue during Q3, but reported earnings showed a $22.31 million loss.

What Is Return On Capital Employed?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.